Cargando…

Modifiable Lifestyle Factors Associated With Response to Treatment in Early Rheumatoid Arthritis

OBJECTIVE: We aimed to evaluate the associations between response to algorithm‐directed treat‐to‐target conventional synthetic disease‐modifying antirheumatic drug therapy and potentially modifiable lifestyle factors, including dietary fish oil supplementation, body mass index (BMI), and smoking his...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brown, Zoe, Metcalf, Robert, Bednarz, Jana, Spargo, Llewellyn, Lee, Anita, Hill, Catherine, Wechalekar, Mihir, Stavrou, Christiana, James, Michael, Cleland, Les, Proudman, Susanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301874/ https://www.ncbi.nlm.nih.gov/pubmed/32453505 http://dx.doi.org/10.1002/acr2.11132

Ejemplares similares

Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years
por: Wabe, Nasir, et al.
Publicado: (2015)

Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis
por: Wiese, Michael D, et al.
Publicado: (2012)

Artificial intelligence and the future of radiographic scoring in rheumatoid arthritis: a viewpoint
por: Bird, Alix, et al.
Publicado: (2022)

Triple DMARD treatment in early rheumatoid arthritis modulates synovial T cell activation and plasmablast/plasma cell differentiation pathways
por: Walsh, Alice M., et al.
Publicado: (2017)

Differential expansion of T peripheral helper cells in early rheumatoid arthritis and osteoarthritis synovium
por: Murray-Brown, William, et al.
Publicado: (2022)

Female reproductive status and exogenous sex hormone use in rheumatoid arthritis patients treated with tocilizumab and csDMARDs
por: Daraghmeh, Dala N, et al.
Publicado: (2022)

Transcriptomic profiling of programmed cell death 1 (PD-1) expressing T cells in early rheumatoid arthritis identifies a decreased CD4 + PD-1 + signature post-treatment
por: Lowe, Katie, et al.
Publicado: (2023)

Using the derived 28-joint disease activity score patient-reported components (DAS28-P) index as a discriminatory measure of response to disease-modifying anti-rheumatic drug therapy in early rheumatoid arthritis
por: Pisaniello, Huai Leng, et al.
Publicado: (2022)

Tocilizumab-induced drug reaction with eosinophilia and systemic symptoms (DRESS) in a patient with rheumatoid arthritis
por: Massolino, Rose I, et al.
Publicado: (2018)

Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2020)

Mortality estimates and excess mortality in rheumatoid arthritis
por: Black, Rachel J, et al.
Publicado: (2023)

Low copy number of the FCGR3B gene and rheumatoid arthritis: a case-control study and meta-analysis
por: Graf, Scott W, et al.
Publicado: (2012)

Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
por: Bhushan, Vandana, et al.
Publicado: (2021)

Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression
por: Guo, Yanxia, et al.
Publicado: (2018)

Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus
por: Cole, Suzanne, et al.
Publicado: (2018)

Editorial: Synovial pathobiology and pathogenesis of inflammatory arthritis
por: Small, Annabelle, et al.
Publicado: (2022)

Nivolumab-induced synovitis is characterized by florid T cell infiltration and rapid resolution with synovial biopsy-guided therapy
por: Murray-Brown, William, et al.
Publicado: (2020)

Concomitant beta-blocker use is associated with a reduced rate of remission in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs: a post hoc multicohort analysis
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2021)

Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients
por: Hopkins, AM, et al.
Publicado: (2015)

Lifestyle Factors and Their Influence on Rheumatoid Arthritis: A Narrative Review
por: Schäfer, Christoph, et al.
Publicado: (2022)

Th17 and Th22 cells in psoriatic arthritis and psoriasis
por: Benham, Helen, et al.
Publicado: (2013)

The association of depression and anxiety with treatment outcomes in patients with rheumatoid arthritis – a pooled analysis of five randomised controlled trials
por: Manning-Bennett, Arkady T., et al.
Publicado: (2022)

The Aetiology of Rheumatoid Arthritis
por: Hill, A. G. S.
Publicado: (1969)

Modifiable cardiovascular risk factors in Rheumatoid Arthritis
por: Wagan, Abrar Ahmed, et al.
Publicado: (2017)

94. Psoriatic arthritis, rheumatoid arthritis or both?
por: Zhang, Jean, et al.
Publicado: (2018)

Correction: Fish oil: what the prescriber needs to know
por: Cleland, Leslie G, et al.
Publicado: (2006)

Fish oil: what the prescriber needs to know
por: Cleland, Leslie G, et al.
Publicado: (2006)

Exploring the treatment burden of disease-modifying anti-rheumatic drug monitoring in people with rheumatoid arthritis
por: Ryan, Sarah, et al.
Publicado: (2023)

Evidence for early disease-modifying drugs in rheumatoid arthritis
por: Scott, David L
Publicado: (2004)

Self-Efficacy and Adherence Behaviors in Rheumatoid Arthritis Patients
por: Oshotse, Christiana, et al.
Publicado: (2018)

Towards prevention of autoantibody-positive rheumatoid arthritis: from lifestyle modification to preventive treatment
por: Gerlag, Danielle M., et al.
Publicado: (2016)

Systematic Evaluation of Rheumatoid Arthritis Risk by Integrating Lifestyle Factors and Genetic Risk Scores
por: Yu, Xing-Hao, et al.
Publicado: (2022)

A multidisciplinary lifestyle program for rheumatoid arthritis: the ‘Plants for Joints’ randomized controlled trial
por: Walrabenstein, Wendy, et al.
Publicado: (2023)

Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia
por: Fletcher, Ashley, et al.
Publicado: (2022)

Endomyocardial biopsy-proven hydroxychloroquine-induced cardiomyopathy in a patient with rheumatoid arthritis
por: Malhotra, Anureet, et al.
Publicado: (2023)

Efficacy and safety of modified-release prednisone in patients with rheumatoid arthritis
por: Krasselt, Marco, et al.
Publicado: (2016)

Impact of Change in Lifestyle and Exercise on Cognitive Function in Patients With Rheumatoid Arthritis: A Systematic Review
por: Akram, Aqsa, et al.
Publicado: (2021)

Impact of lifestyle and comorbidities on seropositive rheumatoid arthritis risk from Korean health insurance data
por: Ro, JunSoo, et al.
Publicado: (2022)

Association of lifestyle and disease characteristics with self-rated wellness/health score in patients with rheumatoid arthritis
por: Tabaraii, Reihane, et al.
Publicado: (2021)

Lifestyle factors in patients with rheumatoid arthritis—a cross-sectional study on two Scandinavian cohorts
por: Karstensen, Julie Katrine, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_njpr9h4sg321hchn6kts1etnov